Nov 25, 2019 by Brian Orelli, PhDA 45% Premium: Here's Why The Medicines Company Is Worth More to Novartis Than It Was to YouUnderstanding why can help you identify the next takeout target.
Nov 23, 2019 by Brian Orelli, PhDSecond RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug ClassAlnylam Pharmaceuticals is coming of age.
Nov 23, 2019 by Brian Orelli, PhDWatch Out, Pfizer: This $2 Billion Biotech Is Coming for YouIt’s David vs. Goliath.
Nov 21, 2019 by Brian Orelli, PhDHere’s Why Shares of Optinose Crashed TodayA secondary offering resets the valuation of the ear, nose, and throat specialist.
Nov 19, 2019 by Brian Orelli, PhDHere’s Why The Medicines Company Jumped Higher Again TodayA buyout rumor has investors hopeful.
Nov 18, 2019 by Brian Orelli, PhDHere's Why The Medicines Company Moved Higher TodayClinical data for cholesterol-lowering drug inclisiran looks good.
Nov 15, 2019 by Brian Orelli, PhDHere’s Why Diplomat Pharmacy Stock Bounced Back 14% TodayVolatility plagues the specialty pharmacy and pharmacy benefit manager.
Nov 13, 2019 by Brian Orelli, PhDHere’s Why Shares of Senseonics Got Hammered TodayIt wasn’t a good quarter for the diabetes-device company.
Nov 12, 2019 by Brian Orelli, PhDHere's Why Diplomat Pharmacy Got Hammered TodayThe loss of a major contract is a serious blow.
Nov 9, 2019 by Brian Orelli, PhDHere's Why HCA Healthcare Rocketed 10.9% Higher in OctoberThe hospital operator's third-quarter results looked robust.
Nov 8, 2019 by Brian Orelli, PhDHere’s Why Centene Jumped 22.7% in OctoberInvestors were smiling at the insurer’s solid third-quarter results.
Nov 7, 2019 by Brian Orelli, PhDHere’s Why Baxter International Fell 12.3% in OctoberAccounting issues overshadowed third-quarter results.
Nov 7, 2019 by Brian Orelli, PhDBetter Buy: GW Pharmaceuticals vs. Corbus PharmaceuticalsIt’s a medical marijuana showdown.
Nov 6, 2019 by Brian Orelli, PhDHere's Why DaVita Stock Jumped TodayThe dialysis company is generating cash and becoming more efficient.
Nov 6, 2019 by Brian Orelli, PhDHere’s Why NuVasive Jumped 11.3% in OctoberA solid third quarter had management increasing 2019 guidance.
Oct 31, 2019 by Brian Orelli, PhDHere's Why Exelixis Sank TodayA slowdown in the biotech’s main franchise shouldn’t have come as a surprise.
Oct 31, 2019 by Brian Orelli, PhDThese Biotechs Were Focused on One Line on Pfizer’s Earnings ReportThe sales figure for Vyndaqel shows the market potential for several smaller players' pipeline candidates.
Oct 31, 2019 by Brian Orelli, PhDCan This Tiny Biotech Take Down Amgen?It’s looking competitive in one cancer drug class.
Oct 30, 2019 by Brian Orelli, PhDHere’s Why Cyclerion Therapeutics Stock Plummeted TodayA double clinical trial failure sends the biotech’s shares down.
Oct 29, 2019 by Brian Orelli, PhDCan New Drugs Help Gilead Sciences Rebound?Management sure hopes so.
![5916202_Givlaari_CartonVial_Angled[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F548920%2F5916202_givlaari_cartonvial_angled1.jpg&w=384&op=resize)
